| bladder cancer |
cisplatin/mitomycin |
N/A |
N/A |
Wang F, et al. [21] |
FEBS Lett.2008 |
| bladder cancer |
cisplatin |
N/A |
Wnt6/Wnt pathway |
Fan Y, et al. [70] |
FEBS J.2014 |
| bladder cancer |
cisplatin/gemcitabine |
N/A |
p-AKT/CREB/miR-196a-5p/p27Kip1 |
Pan J, et al. [71] |
Cancer Lett.2016 |
| breast cancer |
tamoxifen |
N/A |
N/A |
Xu CG, et al. [38] |
Eur Rev Med Pharmacol Sci.2016 |
| breast cancer |
tamoxifen |
N/A |
mTOR pathway |
Wu C, et al. [76] |
Med Sci Monit.2016 |
| breast cancer |
tamoxifen |
miR-18a |
miR-18a, HIF1α |
Li X, et al. [61] |
Tumour Biol.2016 |
| breast cancer |
tamoxifen |
N/A |
Wnt/β-Catenin |
Liu H, et al. [77] |
PLoS One.2016 |
| CML |
imatinib |
miR-16 |
miR-16/MDR1 |
Xiao Y, et al. [62] |
DNA Cell Biol.2016 |
| colorectal cancer |
5-FU |
miR-204-5p |
miR-204-5p/CREB1,Bcl2,RAB22A |
Bian Z, et al. [34] |
Sci Rep.2016 |
| gastric cancer |
doxorubicin/cisplatin/5-FU |
N/A |
miR-27b/Bcl-2,caspase-3 |
Fang Q, et al. [90] |
Med Sci Monit.2016 |
| gastric cancer |
adriamycin |
N/A |
Bcl-2,PARP |
Shang C,et al. [91] |
Cancer Chemother Pharmacol.2016 |
| lung cancer |
EGFR-TKIs |
N/A |
AKT/mTOR/caspase-3,caspase-8 |
Cheng N,et al. [87] |
Oncotarget.2015 |
| ovarian cancer |
cisplatin |
N/A |
SRPK1/Bcl-2,Bax,caspase-3,caspase-9 |
Wang F, et al. [24] |
Neoplasma.2015 |
| ovarian cancer |
platinum-based chemotherapy |
N/A |
N/A |
Zhang L,et al. [74] |
Cancer Chemother Pharmacol.2016 |
| prostate cancer |
docetaxel |
N/A |
miR-204/Sirt1 |
Wang X,et al. [30] |
Cancer Chemother Pharmacol.2016 |
